Vinorelbine tartrate
|
|
|
- CAS-Nr.
- 125317-39-7
- Englisch Name:
- Vinorelbine tartrate
- Synonyma:
- NAVELBINE;VINORELBINE DITARTRATE;NVB;VINORELBINE BITARTRATE;c’-norvincaleukoblastine,3’,4’-didehydro-4’-dioxy-,(r-(r*,r*))-2,3-dihydroxy;Vinorelbin Tartrate;VINORELBINE TARTRATE USP STANDARD;3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine tartrate, KW-2307, NVB, Navelbine tartrate;(2β,3β,4β,5α,12R,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-carboxylicacidmethylester;KW-2307
- CBNumber:
- CB8761554
- Summenformel:
- C53H66N4O20
- Molgewicht:
- 1079.11
- MOL-Datei:
- 125317-39-7.mol
|
Vinorelbine tartrate Eigenschaften
- Schmelzpunkt:
- 181-183°C
- storage temp.
- 2-8°C
- Löslichkeit
- H2O: 10 mg/mL
- Aggregatzustand
- powder
- Farbe
- off-white
- Stabilität:
- Light Sensitive, Temperature Sensitive
- InChIKey
- PMDHUNWDGZSEMN-WTUOTUPFSA-N
- CAS Datenbank
- 125317-39-7(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Kennzeichnung gefährlicher |
Xi |
|
|
| R-Sätze: |
43 |
|
|
| S-Sätze: |
26-36 |
|
|
| RIDADR |
UN 1544PSN1 6.1 / PGII |
|
|
| WGK Germany |
3 |
|
|
| HS Code |
29339900 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H317 |
Kann allergische Hautreaktionen verursachen. |
Sensibilisierung der Haut |
Kategorie 1A |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
|
| Sicherheit |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
|
Vinorelbine tartrate Chemische Eigenschaften,Einsatz,Produktion Methoden
R-Sätze Betriebsanweisung:
R43:Sensibilisierung durch Hautkontakt möglich.
S-Sätze Betriebsanweisung:
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.
Chemische Eigenschaften
Pale Yellow Powder
Definition
ChEBI: The L-(+)-tartrate salt of vinorelbine.
Allgemeine Beschreibung
Vinorelbine ditartrate is available in 1- and 5-mL vials at aconcentration of 10 mg/mL for IV use. It is FDA approvedfor the treatment of NSCLC. The agent has also been usedin treating metastatic breast cancer, cervical cancer, uterinecancer, and lung cancer especially in older patients or thosewith physical difficulties. Vinorelbine is the most lipophilicof the vinca alkaloids because of modifications of thecatharanthine ring system and dehydration of the piperidinering. This allows the agent to be quickly taken up into cellsincluding lung tissue where concentrations are 300-foldhigher than plasma concentrations. This is 3 to 13 timeshigher than the lung concentrations seen with vincristine.The agent is highly protein bound (80%–91%) and metabolizedby CYP3A. The major metabolite seen is the 4-Odesacetylderivative, which is equally active with the parentbut only formed in small quantities. The agent is eliminatedprimarily (33%–88%) in the bile with some appearing inthe urine (16%–30%). The elimination half-life is 27 to43 hours. The toxicities seen for vinorelbine includemyelosuppression, which is dose limiting but ceases upondiscontinuation of drug. This is most commonly seen as aneutropenia, and patient’s neutrophil count should be monitoredprior to and during therapy to decrease the chanceof infection. Additional toxicities include nausea/vomiting,elevation of liver function tests, alopecia, generalized fatigue，and inappropriate secretion of antidiuretic hormone.Neurotoxicity is seen with vinorelbine but occurs to a lesserdegree compared with other vinca alkaloids because of itsdecreased affinity for axonal microtubules.
Biologische Aktivität
Selective mitotic microtubule antagonist that exhibits > 20 fold selectivity over axonal microtubules. Inhibits proliferation of multiple human tumor cell lines (IC 50 = 1.25 nM in HeLa cells) and blocks metaphase/anaphase transition by suppression of microtubule dynamics (IC 50 = 3.8 nM). Reduces spindle length by 29% and inhibits microtubule polymerization at micromolar concentrations.
Vinorelbine tartrate Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Vinorelbine tartrate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 531)Lieferanten
125317-39-7()Verwandte Suche:
- VINORELBINEDITARTRATE SALT HYDRATE
- VINORELBINE TARTRATE, NAVELBINE
- VINORELBINE RELATED COMPOUND A4-O-DEACETYLVINORELBINE TARTRATE USP STANDARD
- VINORELBINE TARTRATE, USP
- VinorelbineTartrateUsp28
- butanedioate(1:2)
- NAVELBINE TARTRATE
- VINORELBINE DITARTARIC ACID
- VINORELBINE DITARTRATE SALT
- VINORELBINE TARTRATE
- VINORELBINE(RG)
- Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2b,3b,4b,5a,12b,19a)-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (salt)
- Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2b,3b,4b,5a,12R,19a)-, (2R,3R)-2,3-dih
- C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:2) (salt)
- Navelbine ditartrate
- Nor-5'-anhydrovinblastine ditartrate
- 5'-NORANHYDROVINOBLASTINE TARTRATE
- 3',4'-DIDEHYDRO-4'-DEOXY-C'-NORVINCALEUKOBLASTINE [R-(R*,R*)-2-3-DIHYDROXYBUTANEDIOATE (1:2) SALT]
- Pacilitaxel
- Vinorelbine ditartrate, Vinorelbine bitartrate, VRLB,KW – 2307 NVB
- KW-2307
- Vinorelbine Bitartarate
- Vinorelbine ditartrate salt hydrate,3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine tartrate, KW-2307, NVB, Navelbine tartr
- Vinorelbine Tartrate (200 mg)
- Methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(1R,12S,14R)-16-ethyl-12-(Methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0^{3,11}.0^{4,9}]octadeca-3(11),4(9),5,7,15-pentaen-12-yl]-10-hydroxy-5-Methoxy-8-Methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0
- Vinorelbine ditartate
- lbine Ditartrate
- Vinoreline Tartrate
- 5μ-Noranhydrovinoblastine tartrate, KW-2307, Navelbine tartrate, NVB, 3μ,4μ-Didehydro-4μ-deoxy-Cμ-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt]
- Vinorelbine hydrate ditartrate salt
- Vinorelbine Tartrate USP/EP
- 3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine Ditartrate
- Eunades
- Vinorelbin artrate
- vinorelbine L-tartrate
- Vinorelbine Ditartrate salt hydrate, ≥98%(HPLC)
- Vinorelbine tartrate CRS
- Vinorelbine tartrate cas 125317-39-7
- inorelbine tartrate
- Vinorelbine tartrate USP/EP/BP
- Vinorelbine Bitartrate (10mM in DMSO)
- Vinorelbine ditartrate (KW-2307)
- Vinorelbine DitartrateQ: What is
Vinorelbine Ditartrate Q: What is the CAS Number of
Vinorelbine Ditartrate Q: What is the storage condition of
Vinorelbine Ditartrate Q: What are the applications of
Vinorelbine Ditartrate
- Vinorelbine-D3 DitartrateQ: What is
Vinorelbine-D3 Ditartrate Q: What is the CAS Number of
Vinorelbine-D3 Ditartrate
- Vinorelbine Tartrate (1714506)
- 3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine tartrate, KW-2307, NVB, Navelbine tartrate
- VINORELBINE TARTRATE USP STANDARD
- c’-norvincaleukoblastine,3’,4’-didehydro-4’-dioxy-,(r-(r*,r*))-2,3-dihydroxy
- NVB
- NAVELBINE
- VINORELBINE BITARTRATE
- VINORELBINE DITARTRATE
- Vinorelbin Tartrate
- (2β,3β,4β,5α,12R,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-carboxylicacidmethylester
- Atorvastatin Impurity 145
- Methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((8R)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis((2R,3R)-2,3-dihydroxysuccinate)
- 125317-39-7
- C49H60N4O14
